| The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study |
nhummel |
Mar 3, 2015 11:23:07 AM |
| Modeling the progression of rheumatoid arthritis: A two-country model to estimate costs and consequences of rheumatoid arthritis |
nhummel |
Mar 3, 2015 11:21:14 AM |
| The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis |
nhummel |
Mar 3, 2015 8:51:03 AM |
| Simultaneous Exposure–Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol |
nhummel |
Mar 3, 2015 8:33:56 AM |
| A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis |
nhummel |
Mar 3, 2015 8:33:35 AM |
| Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective |
nhummel |
Mar 3, 2015 8:25:34 AM |
| Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands: Cost Effectiveness of TNF-Blocking Treatment |
nhummel |
Mar 3, 2015 8:23:25 AM |
| The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice |
nhummel |
Mar 3, 2015 8:14:16 AM |
| Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment |
nhummel |
Mar 2, 2015 5:05:54 PM |
| The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis |
nhummel |
Mar 2, 2015 4:03:38 PM |
